Your browser doesn't support javascript.
loading
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5ß1 integrin monoclonal antibody (volociximab) in cancer patients.
Ng, Chee M; Bai, S; Takimoto, C H; Tang, M T; Tolcher, A W.
Affiliation
  • Ng CM; Cancer Therapy and Research Center, Institute for Drug Development, The University of Texas Health Science Center at San Antonio, San Antonio, 78229, USA. ng.cheem@yahoo.com
Cancer Chemother Pharmacol ; 65(2): 207-17, 2010 Jan.
Article in En | MEDLINE | ID: mdl-19468731
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Angiogenesis Inhibitors / Integrin alpha5beta1 / Models, Biological / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2010 Document type: Article Affiliation country: United States Country of publication: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Angiogenesis Inhibitors / Integrin alpha5beta1 / Models, Biological / Antibodies, Monoclonal Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2010 Document type: Article Affiliation country: United States Country of publication: Germany